{
    "functional_evidence_assessment": [
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "G",
                    "alt": "S",
                    "position": "2019"
                },
                "variant_string_id": "LRRK2 G2019S"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Mutations in the LRRK2 gene cause late - onset PD. Little is known about how LRRK2 is regulated, what its physiological substrates are or how mutations affect LRRK2 function. The study suggests that over - activation of LRRK2 predisposes humans to develop PD.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly states that LRRK2 mutations cause late - onset PD and implies a role of LRRK2 over - activation in the disease mechanism.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "A KESTREL screen was used to identify proteins phosphorylated by LRRK2. Also, assays were developed to measure LRRK2 kinase activity using substrates like moesin, MBP, and LRRKtide.",
                    "judgment": "Yes",
                    "reasoning": "The kinase activity assays and substrate identification screen are relevant to the proposed disease mechanism of LRRK2 over - activation in PD.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "Sub - step 3a: Assays were set up in a total volume of 25 µl or 50 µl containing specific amounts of LRRK2, substrates (moesin, MBP, LRRKtide), MgCl₂, and [γ - 32P]ATP. Reactions were carried out in triplicate. Wild - type and kinase - inactive (D2017A) LRRK2 were used as controls. Sub - step 3c: No information on using known pathogenic or benign variants as controls was found.",
                    "judgment": "Yes",
                    "reasoning": "For sub - step 3a, basic controls (wild - type and kinase - inactive mutant) were used, and experiments were performed in triplicate. Since basic controls and replicates were sufficient, we move to sub - step 3c. As no variant controls were used, according to the flowchart, we go to the maximum supporting level for evidence strength.",
                    "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "Based on the ACMG functional evidence evaluation flowchart, the G2019S variant in LRRK2 has supporting pathogenic evidence. The disease mechanism of LRRK2 - related PD was defined, the assays were applicable, basic controls and replicates were used, but no variant controls were employed, resulting in a PS3_supporting strength rating."
        },
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "R",
                    "alt": "H",
                    "position": "1941"
                },
                "variant_string_id": "LRRK2 R1941H"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Mutations in the LRRK2 gene cause late - onset PD. Little is known about how LRRK2 is regulated, what its physiological substrates are or how mutations affect LRRK2 function. The study suggests that over - activation of LRRK2 predisposes humans to develop PD.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly states that LRRK2 mutations cause late - onset PD and implies a role of LRRK2 over - activation in the disease mechanism.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "A KESTREL screen was used to identify proteins phosphorylated by LRRK2. Also, assays were developed to measure LRRK2 kinase activity using substrates like moesin, MBP, and LRRKtide.",
                    "judgment": "Yes",
                    "reasoning": "The kinase activity assays and substrate identification screen are relevant to the proposed disease mechanism of LRRK2 over - activation in PD.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "Sub - step 3a: Assays were set up in a total volume of 25 µl or 50 µl containing specific amounts of LRRK2, substrates (moesin, MBP, LRRKtide), MgCl₂, and [γ - 32P]ATP. Reactions were carried out in triplicate. Wild - type and kinase - inactive (D2017A) LRRK2 were used as controls. Sub - step 3c: No information on using known pathogenic or benign variants as controls was found.",
                    "judgment": "Yes",
                    "reasoning": "For sub - step 3a, basic controls (wild - type and kinase - inactive mutant) were used, and experiments were performed in triplicate. Since basic controls and replicates were sufficient, we move to sub - step 3c. As no variant controls were used, according to the flowchart, we go to the maximum supporting level for evidence strength.",
                    "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "Based on the ACMG functional evidence evaluation flowchart, the R1941H variant in LRRK2 has supporting pathogenic evidence. The disease mechanism of LRRK2 - related PD was defined, the assays were applicable, basic controls and replicates were used, but no variant controls were employed, resulting in a PS3_supporting strength rating."
        },
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "I",
                    "alt": "T",
                    "position": "2012"
                },
                "variant_string_id": "LRRK2 I2012T"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Mutations in the LRRK2 gene cause late - onset PD. Little is known about how LRRK2 is regulated, what its physiological substrates are or how mutations affect LRRK2 function. The study suggests that over - activation of LRRK2 predisposes humans to develop PD.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly states that LRRK2 mutations cause late - onset PD and implies a role of LRRK2 over - activation in the disease mechanism.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "A KESTREL screen was used to identify proteins phosphorylated by LRRK2. Also, assays were developed to measure LRRK2 kinase activity using substrates like moesin, MBP, and LRRKtide.",
                    "judgment": "Yes",
                    "reasoning": "The kinase activity assays and substrate identification screen are relevant to the proposed disease mechanism of LRRK2 over - activation in PD.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "Sub - step 3a: Assays were set up in a total volume of 25 µl or 50 µl containing specific amounts of LRRK2, substrates (moesin, MBP, LRRKtide), MgCl₂, and [γ - 32P]ATP. Reactions were carried out in triplicate. Wild - type and kinase - inactive (D2017A) LRRK2 were used as controls. Sub - step 3c: No information on using known pathogenic or benign variants as controls was found.",
                    "judgment": "Yes",
                    "reasoning": "For sub - step 3a, basic controls (wild - type and kinase - inactive mutant) were used, and experiments were performed in triplicate. Since basic controls and replicates were sufficient, we move to sub - step 3c. As no variant controls were used, according to the flowchart, we go to the maximum supporting level for evidence strength.",
                    "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "Based on the ACMG functional evidence evaluation flowchart, the I2012T variant in LRRK2 has supporting pathogenic evidence. The disease mechanism of LRRK2 - related PD was defined, the assays were applicable, basic controls and replicates were used, but no variant controls were employed, resulting in a PS3_supporting strength rating."
        },
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "I",
                    "alt": "T",
                    "position": "2020"
                },
                "variant_string_id": "LRRK2 I2020T"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Mutations in the LRRK2 gene cause late - onset PD. Little is known about how LRRK2 is regulated, what its physiological substrates are or how mutations affect LRRK2 function. The study suggests that over - activation of LRRK2 predisposes humans to develop PD.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly states that LRRK2 mutations cause late - onset PD and implies a role of LRRK2 over - activation in the disease mechanism.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "A KESTREL screen was used to identify proteins phosphorylated by LRRK2. Also, assays were developed to measure LRRK2 kinase activity using substrates like moesin, MBP, and LRRKtide.",
                    "judgment": "Yes",
                    "reasoning": "The kinase activity assays and substrate identification screen are relevant to the proposed disease mechanism of LRRK2 over - activation in PD.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "Sub - step 3a: Assays were set up in a total volume of 25 µl or 50 µl containing specific amounts of LRRK2, substrates (moesin, MBP, LRRKtide), MgCl₂, and [γ - 32P]ATP. Reactions were carried out in triplicate. Wild - type and kinase - inactive (D2017A) LRRK2 were used as controls. Sub - step 3c: No information on using known pathogenic or benign variants as controls was found.",
                    "judgment": "Yes",
                    "reasoning": "For sub - step 3a, basic controls (wild - type and kinase - inactive mutant) were used, and experiments were performed in triplicate. Since basic controls and replicates were sufficient, we move to sub - step 3c. As no variant controls were used, according to the flowchart, we go to the maximum supporting level for evidence strength.",
                    "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "Based on the ACMG functional evidence evaluation flowchart, the I2020T variant in LRRK2 has supporting pathogenic evidence. The disease mechanism of LRRK2 - related PD was defined, the assays were applicable, basic controls and replicates were used, but no variant controls were employed, resulting in a PS3_supporting strength rating."
        },
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "G",
                    "alt": "R",
                    "position": "2385"
                },
                "variant_string_id": "LRRK2 G2385R"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Mutations in the LRRK2 gene cause late - onset PD. Little is known about how LRRK2 is regulated, what its physiological substrates are or how mutations affect LRRK2 function. The study suggests that over - activation of LRRK2 predisposes humans to develop PD.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly states that LRRK2 mutations cause late - onset PD and implies a role of LRRK2 over - activation in the disease mechanism.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "A KESTREL screen was used to identify proteins phosphorylated by LRRK2. Also, assays were developed to measure LRRK2 kinase activity using substrates like moesin, MBP, and LRRKtide.",
                    "judgment": "Yes",
                    "reasoning": "The kinase activity assays and substrate identification screen are relevant to the proposed disease mechanism of LRRK2 over - activation in PD.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "Sub - step 3a: Assays were set up in a total volume of 25 µl or 50 µl containing specific amounts of LRRK2, substrates (moesin, MBP, LRRKtide), MgCl₂, and [γ - 32P]ATP. Reactions were carried out in triplicate. Wild - type and kinase - inactive (D2017A) LRRK2 were used as controls. Sub - step 3c: No information on using known pathogenic or benign variants as controls was found.",
                    "judgment": "Yes",
                    "reasoning": "For sub - step 3a, basic controls (wild - type and kinase - inactive mutant) were used, and experiments were performed in triplicate. Since basic controls and replicates were sufficient, we move to sub - step 3c. As no variant controls were used, according to the flowchart, we go to the maximum supporting level for evidence strength.",
                    "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "Based on the ACMG functional evidence evaluation flowchart, the G2385R variant in LRRK2 has supporting pathogenic evidence. The disease mechanism of LRRK2 - related PD was defined, the assays were applicable, basic controls and replicates were used, but no variant controls were employed, resulting in a PS3_supporting strength rating."
        },
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "R",
                    "alt": "C",
                    "position": "1441"
                },
                "variant_string_id": "LRRK2 R1441C"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Mutations